Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Mordor Intelligence | PRODUCT CODE: 707232

Cover Image

PUBLISHER: Mordor Intelligence | PRODUCT CODE: 707232

Recombinant DNA (rDNA) Technology Market - Growth, Trends, and Forecasts (2022 - 2027)

PUBLISHED:
PAGES: 115 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 4750
PDF & Excel (Team License: Up to 7 Users)
USD 5250
PDF & Excel (Site License)
USD 6500
PDF & Excel (Corporate License)
USD 8750

Add to Cart

Recombinant DNA technology (RDT) is essential for improving health conditions, primarily by developing new vaccines and pharmaceuticals. Moreover, the treatment strategies are improved by developing diagnostics kits, monitoring devices, and new therapeutic approaches. Additionally, many other industries are benefiting from the research conducted on genetically modified organisms (GMO), such as microorganisms that are considered as clean fuel producers and bio degraders. Genetically modified vaccines are developed for curing various diseases in humans and plants. The recombinant DNA technology created several potential innovation opportunities for developing a wide range of therapeutic products, with immediate effect in medical genetics and biomedicine, by modifying microorganisms, animals, and plants, in order to yield medically useful substances. Therefore, the increasing demand and application of RDT in various sectors are driving the growth of the market studied.

Key Market Trends

The Food and Agriculture segment is Expected to Register the Highest CAGR over the Forecast period

In agriculture, the development of genetically modified crops, in order to improve both yield and resistance to pests or herbicides, is gaining a high degree of public acceptance. The genetically modified tomato, CGN-89564-2, was the first commercially grown, genetically engineered crop product to be granted a license for human consumption. Additionally, DNA molecular marker technology is important for preservation, identification, evaluation, mining, and innovation of plant germplasm resources. The introduction of a genetically modified fruit paved the way for the use of GMOs in food. Currently, genetic modification is witnessing a widespread adoption. Thus, increasing the application of RDT in agriculture and food is expected to drive the growth of the market studied.

The North American region is Expected to Dominate the Market Over the Forecast Period

The North American region is expected to dominate the market studied over the forecast period. In the North America region, the United States accounts for the largest market share, primarily due to the presence of numerous biopharmaceutical manufacturing companies and the presence of effective regulatory bodies to monitor the various ethical and scientific concerns, pertaining to the use of technology. This is expected to drive the market's growth, especially in the North American region.

Competitive Landscape

The Recombinant DNA (rDNA) Technology market is competitive, with the presence of both major players and small players. In terms of market share, the major players are currently dominating the market. Some of the major market players include GenScript, New England Biolabs, GlaxoSmithKline Plc, Pfizer, and Sanofi, among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
Product Code: 62776

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Technological Advancements in Genomics
    • 4.2.2 Expansion of Biopharmaceutical Industry
    • 4.2.3 Increasing Demand and Applications of Recombinant/ Genetically Modified Products
  • 4.3 Market Restraints
    • 4.3.1 Regulatory, Scientific, and Ethical Challenges Associated with Gene Therapy
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product
    • 5.1.1 Medical
      • 5.1.1.1 Therapeutic Agent
      • 5.1.1.2 Human Protein
      • 5.1.1.3 Vaccine
    • 5.1.2 Non-medical
      • 5.1.2.1 Biotech Crops
      • 5.1.2.2 Specialty Chemicals
      • 5.1.2.3 Other Non-medical Products
  • 5.2 By Component
    • 5.2.1 Expression System
    • 5.2.2 Cloning Vector
  • 5.3 By Application
    • 5.3.1 Food and Agriculture
    • 5.3.2 Health and Disease
    • 5.3.3 Environment
    • 5.3.4 Other Applications
  • 5.4 By End User
    • 5.4.1 Biotechnology and Pharmaceutical Companies
    • 5.4.2 Academic and Government Research Institutes
    • 5.4.3 Other End Users
  • 5.5 Geography
    • 5.5.1 North America
      • 5.5.1.1 United States
      • 5.5.1.2 Canada
      • 5.5.1.3 Mexico
    • 5.5.2 Europe
      • 5.5.2.1 Germany
      • 5.5.2.2 United Kingdom
      • 5.5.2.3 France
      • 5.5.2.4 Italy
      • 5.5.2.5 Spain
      • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
      • 5.5.3.1 China
      • 5.5.3.2 Japan
      • 5.5.3.3 India
      • 5.5.3.4 Australia
      • 5.5.3.5 South korea
      • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle-East & Africa
      • 5.5.4.1 GCC
      • 5.5.4.2 South Africa
      • 5.5.4.3 Rest of Middle-East & Africa
    • 5.5.5 South America
      • 5.5.5.1 Brazil
      • 5.5.5.2 Argentina
      • 5.5.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Amgen Inc.
    • 6.1.2 Eli Lilly and Company
    • 6.1.3 F. Hoffmann-La Roche Ltd (Genentech Inc.)
    • 6.1.4 GenScript
    • 6.1.5 Merck KGaA
    • 6.1.6 New England Biolabs
    • 6.1.7 Novartis AG
    • 6.1.8 Novo Nordisk A/S
    • 6.1.9 Pfizer Inc.
    • 6.1.10 Sanofi

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!